CA2850293C - Hpv chimaeric particle - Google Patents
Hpv chimaeric particle Download PDFInfo
- Publication number
- CA2850293C CA2850293C CA2850293A CA2850293A CA2850293C CA 2850293 C CA2850293 C CA 2850293C CA 2850293 A CA2850293 A CA 2850293A CA 2850293 A CA2850293 A CA 2850293A CA 2850293 C CA2850293 C CA 2850293C
- Authority
- CA
- Canada
- Prior art keywords
- hpv
- chimaeric
- polypeptide
- seq
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002245 particle Substances 0.000 title claims abstract description 11
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 46
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 14
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 14
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 14
- 208000009608 Papillomavirus Infections Diseases 0.000 claims abstract description 11
- 241000700605 Viruses Species 0.000 claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims description 119
- 108090000623 proteins and genes Proteins 0.000 claims description 116
- 102000004169 proteins and genes Human genes 0.000 claims description 99
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 91
- 210000004027 cell Anatomy 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 230000004044 response Effects 0.000 claims description 33
- 101710101547 Non-structural protein NS-S Proteins 0.000 claims description 32
- 239000013604 expression vector Substances 0.000 claims description 29
- 210000003763 chloroplast Anatomy 0.000 claims description 24
- 230000028993 immune response Effects 0.000 claims description 21
- 230000003472 neutralizing effect Effects 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 210000000805 cytoplasm Anatomy 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 238000001764 infiltration Methods 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000032361 posttranscriptional gene silencing Effects 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 7
- 230000005875 antibody response Effects 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 241000016010 Tomato spotted wilt orthotospovirus Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000011536 extraction buffer Substances 0.000 claims description 5
- 230000004807 localization Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 241000710145 Tomato bushy stunt virus Species 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 241000341655 Human papillomavirus type 16 Species 0.000 description 144
- 241000251188 Holocephali Species 0.000 description 140
- 108091007433 antigens Proteins 0.000 description 117
- 102000036639 antigens Human genes 0.000 description 117
- 239000000427 antigen Substances 0.000 description 116
- 241000251477 Chimaera Species 0.000 description 102
- 230000014509 gene expression Effects 0.000 description 101
- 229960005486 vaccine Drugs 0.000 description 101
- 235000018102 proteins Nutrition 0.000 description 89
- 238000006386 neutralization reaction Methods 0.000 description 66
- 239000013598 vector Substances 0.000 description 62
- 238000000746 purification Methods 0.000 description 47
- 238000001262 western blot Methods 0.000 description 42
- 238000003556 assay Methods 0.000 description 39
- 239000000419 plant extract Substances 0.000 description 39
- 239000013642 negative control Substances 0.000 description 38
- 238000010790 dilution Methods 0.000 description 36
- 239000012895 dilution Substances 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 239000013641 positive control Substances 0.000 description 29
- 238000002965 ELISA Methods 0.000 description 28
- 101000742340 Human papillomavirus type 16 Minor capsid protein L2 Proteins 0.000 description 25
- 235000001014 amino acid Nutrition 0.000 description 25
- 238000001514 detection method Methods 0.000 description 24
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 20
- 238000004587 chromatography analysis Methods 0.000 description 20
- 229960002897 heparin Drugs 0.000 description 20
- 229920000669 heparin Polymers 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- 241000238631 Hexapoda Species 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 230000005847 immunogenicity Effects 0.000 description 16
- 241000589158 Agrobacterium Species 0.000 description 15
- 229940124957 Cervarix Drugs 0.000 description 15
- 230000030279 gene silencing Effects 0.000 description 15
- 239000012521 purified sample Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 239000012528 membrane Substances 0.000 description 13
- 229960002566 papillomavirus vaccine Drugs 0.000 description 13
- 230000000903 blocking effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000207746 Nicotiana benthamiana Species 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000004448 titration Methods 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 8
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 230000010474 transient expression Effects 0.000 description 8
- 108010064851 Plant Proteins Proteins 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 235000021118 plant-derived protein Nutrition 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 108010031100 chloroplast transit peptides Proteins 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000001976 enzyme digestion Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 239000012474 protein marker Substances 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000004627 transmission electron microscopy Methods 0.000 description 5
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 4
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000208125 Nicotiana Species 0.000 description 4
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000000326 densiometry Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000000286 energy filtered transmission electron microscopy Methods 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108700031455 Bovine papillomavirus L2 Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 101150057615 Syn gene Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000000954 titration curve Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 101000717362 Acetabularia peniculus Ribulose bisphosphate carboxylase small subunit, chloroplastic 7 Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101000742305 Bean yellow dwarf virus Replication-associated protein Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101710121996 Hexon protein p72 Proteins 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- OJOBTAOGJIWAGB-UHFFFAOYSA-N acetosyringone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1O OJOBTAOGJIWAGB-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003312 immunocapture Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 229940032313 prophylactic HPV vaccine Drugs 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 108010006808 stromal processing peptidase Proteins 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241001569772 Celithemis elisa Species 0.000 description 1
- 101710134884 Chalcone synthase 5 Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108010046914 Exodeoxyribonuclease V Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 description 1
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 101000641177 Human papillomavirus type 16 Major capsid protein L1 Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 101150075239 L1 gene Proteins 0.000 description 1
- 101150027802 L2 gene Proteins 0.000 description 1
- 238000003231 Lowry assay Methods 0.000 description 1
- 238000009013 Lowry's assay Methods 0.000 description 1
- 241000227653 Lycopersicon Species 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000012518 Poros HS 50 resin Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001112090 Pseudovirus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710090029 Replication-associated protein A Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
- 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011968 cross flow microfiltration Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- FSVCQIDHPKZJSO-UHFFFAOYSA-L nitro blue tetrazolium dichloride Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 FSVCQIDHPKZJSO-UHFFFAOYSA-L 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000002023 papillomaviral effect Effects 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 231100000009 visible necrosis Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA2011/08841 | 2011-12-01 | ||
| ZA201108841 | 2011-12-01 | ||
| PCT/IB2012/056912 WO2013080187A1 (en) | 2011-12-01 | 2012-12-03 | Hpv chimaeric particle |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2850293A1 CA2850293A1 (en) | 2013-06-06 |
| CA2850293C true CA2850293C (en) | 2019-10-08 |
Family
ID=48534756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2850293A Expired - Fee Related CA2850293C (en) | 2011-12-01 | 2012-12-03 | Hpv chimaeric particle |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9771397B2 (enExample) |
| EP (1) | EP2785842A4 (enExample) |
| JP (1) | JP6228922B2 (enExample) |
| KR (1) | KR102013801B1 (enExample) |
| CN (1) | CN103890177B (enExample) |
| AU (1) | AU2012345443B2 (enExample) |
| BR (1) | BR112014012491A2 (enExample) |
| CA (1) | CA2850293C (enExample) |
| HK (1) | HK1198703A1 (enExample) |
| IL (1) | IL232584B (enExample) |
| IN (1) | IN2014DN03054A (enExample) |
| MX (1) | MX355352B (enExample) |
| MY (1) | MY184076A (enExample) |
| PH (1) | PH12014500466A1 (enExample) |
| RU (1) | RU2642287C2 (enExample) |
| SG (1) | SG11201401579UA (enExample) |
| WO (1) | WO2013080187A1 (enExample) |
| ZA (1) | ZA201403557B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107252489A (zh) | 2009-04-13 | 2017-10-17 | 法国健康和医学研究院 | Hpv颗粒及其用途 |
| US9700639B2 (en) | 2012-02-07 | 2017-07-11 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| MX385842B (es) * | 2013-09-18 | 2025-03-18 | Aura Biosciences Inc | Conjugados de partículas de tipo virus y uso de las mismas. |
| CN104531741B (zh) * | 2014-08-22 | 2016-08-24 | 天津康希诺生物技术有限公司 | 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用 |
| CN105801704B (zh) * | 2014-12-31 | 2020-06-02 | 艾托金生物医药（苏州）有限公司 | 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用 |
| EP3827846B1 (en) | 2015-08-18 | 2024-10-02 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
| CN114699525A (zh) | 2015-08-18 | 2022-07-05 | 乐天医药生技股份有限公司 | 酞菁染料偶联物的制造方法及稳定偶联物 |
| AU2016343722A1 (en) | 2015-10-30 | 2018-05-24 | Aleta Biotherapeutics, Inc. | Targeted cancer therapy |
| BR112019020853A2 (pt) | 2017-04-04 | 2020-05-12 | Avidea Technologies, Inc. | Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune |
| MX2019015769A (es) | 2017-06-23 | 2020-08-03 | Verimmune Inc | Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno. |
| JP7641005B2 (ja) | 2018-12-27 | 2025-03-06 | ヴェリミューン インコーポレイテッド | コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用 |
| CA3147849A1 (en) | 2019-07-19 | 2021-01-28 | Sinocelltech Ltd. | Polyvalent immunogenicity composition for human papillomavirus |
| WO2021161179A1 (en) * | 2020-02-10 | 2021-08-19 | University Of Cape Town | Plant produced bovine papillomavirus virus-like particles and pseudovirions |
| MX2023004465A (es) | 2020-10-19 | 2023-06-19 | Verimmune Inc | Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer. |
| KR102821363B1 (ko) | 2023-02-06 | 2025-06-13 | 영산대학교산학협력단 | 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9507657A (pt) * | 1994-05-16 | 1997-09-09 | Merck & Co Inc | Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte |
| PL347472A1 (en) | 1998-08-14 | 2002-04-08 | Merck & Co Inc | Process for purifying human papillomavirus virus-like particles |
| US20020016372A1 (en) * | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
| WO2003068163A2 (en) | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Optimization of gene sequences of chimeric virus-like particles for expression in insect cells |
| PT1506222E (pt) | 2002-05-17 | 2009-06-12 | Univ Cape Town | Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas |
| WO2006119516A2 (en) | 2005-04-29 | 2006-11-09 | University Of Cape Town | Expression of viral proteins in plants |
| CN102458440A (zh) * | 2009-04-10 | 2012-05-16 | 约翰·霍普金斯大学 | 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp) |
| AU2009348078B2 (en) | 2009-06-19 | 2013-03-14 | Eyegene Inc. | Vaccine for cervical cancer |
| PE20120563A1 (es) | 2009-06-25 | 2012-05-17 | Glaxosmithkline Biolog Sa | Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv |
| WO2011077371A1 (en) * | 2009-12-22 | 2011-06-30 | University Of Cape Town | Method for enhancing the expression of hpv l1 |
-
2012
- 2012-12-03 KR KR1020147010686A patent/KR102013801B1/ko not_active Expired - Fee Related
- 2012-12-03 BR BR112014012491A patent/BR112014012491A2/pt not_active IP Right Cessation
- 2012-12-03 SG SG11201401579UA patent/SG11201401579UA/en unknown
- 2012-12-03 PH PH1/2014/500466A patent/PH12014500466A1/en unknown
- 2012-12-03 RU RU2014126587A patent/RU2642287C2/ru not_active IP Right Cessation
- 2012-12-03 MY MYPI2014700894A patent/MY184076A/en unknown
- 2012-12-03 HK HK14112143.5A patent/HK1198703A1/xx unknown
- 2012-12-03 JP JP2014544038A patent/JP6228922B2/ja not_active Expired - Fee Related
- 2012-12-03 EP EP12853360.1A patent/EP2785842A4/en not_active Withdrawn
- 2012-12-03 WO PCT/IB2012/056912 patent/WO2013080187A1/en not_active Ceased
- 2012-12-03 MX MX2014006520A patent/MX355352B/es active IP Right Grant
- 2012-12-03 CA CA2850293A patent/CA2850293C/en not_active Expired - Fee Related
- 2012-12-03 US US14/360,524 patent/US9771397B2/en not_active Expired - Fee Related
- 2012-12-03 CN CN201280052968.8A patent/CN103890177B/zh not_active Expired - Fee Related
- 2012-12-03 AU AU2012345443A patent/AU2012345443B2/en not_active Ceased
- 2012-12-03 IN IN3054DEN2014 patent/IN2014DN03054A/en unknown
-
2014
- 2014-05-13 IL IL232584A patent/IL232584B/en active IP Right Grant
- 2014-05-16 ZA ZA2014/03557A patent/ZA201403557B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12014500466A1 (en) | 2022-05-11 |
| BR112014012491A2 (pt) | 2017-06-06 |
| EP2785842A4 (en) | 2015-11-25 |
| NZ622595A (en) | 2016-04-29 |
| IL232584B (en) | 2018-10-31 |
| MX355352B (es) | 2018-04-17 |
| US20140377367A1 (en) | 2014-12-25 |
| MY184076A (en) | 2021-03-17 |
| JP6228922B2 (ja) | 2017-11-08 |
| IN2014DN03054A (enExample) | 2015-05-15 |
| CN103890177B (zh) | 2016-03-09 |
| CA2850293A1 (en) | 2013-06-06 |
| JP2015500229A (ja) | 2015-01-05 |
| AU2012345443A1 (en) | 2014-04-17 |
| EP2785842A1 (en) | 2014-10-08 |
| RU2014126587A (ru) | 2016-01-27 |
| IL232584A0 (en) | 2014-06-30 |
| KR20140098061A (ko) | 2014-08-07 |
| RU2642287C2 (ru) | 2018-01-24 |
| AU2012345443B2 (en) | 2017-10-26 |
| HK1198703A1 (en) | 2015-05-29 |
| US9771397B2 (en) | 2017-09-26 |
| WO2013080187A1 (en) | 2013-06-06 |
| MX2014006520A (es) | 2014-11-21 |
| CN103890177A (zh) | 2014-06-25 |
| SG11201401579UA (en) | 2014-07-30 |
| ZA201403557B (en) | 2020-10-28 |
| KR102013801B1 (ko) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2850293C (en) | Hpv chimaeric particle | |
| Pineo et al. | Immunogenic assessment of plant‐produced human papillomavirus type 16 L1/L2 chimaeras | |
| EP2477650B1 (en) | Virus like particles comprising target proteins fused to plant viral coat proteins | |
| EP1545625B1 (en) | Flexible vaccine assembly and vaccine delivery platform | |
| CA2855252C (en) | Influenza virus-like particles (vlps) comprising hemagglutinin produced in nicotiana tabacum | |
| JP7145083B2 (ja) | 高等植物の葉緑体におけるトランス遺伝子発現を増加させるためのコドン最適化及びリボソームプロファイリング | |
| JP2017528137A (ja) | 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン | |
| Muthamilselvan et al. | Assembly of human papillomavirus 16 L1 protein in Nicotiana benthamiana chloroplasts into highly immunogenic virus-like particles | |
| JP2023539356A (ja) | 改変コロナウイルス構造タンパク質 | |
| CN103667319B (zh) | 抗人乳头瘤病毒的三价疫苗及其制法和用途 | |
| WO2011077371A1 (en) | Method for enhancing the expression of hpv l1 | |
| CN116925195B (zh) | 一种基于新型冠状病毒的mRNA疫苗 | |
| NZ622595B2 (en) | Hpv chimaeric particle | |
| EP1401493B1 (en) | Subunit vaccines and processes for the production thereof | |
| Meshcheryakova et al. | Cowpea mosaic virus chimeric particles bearing the ectodomain of matrix protein 2 (M2E) of the influenza A virus: production and characterization | |
| Pineo | Plant production and immunogenic characterisation of Human papillomavirus chimaeric vaccines | |
| Hefferon | Applications of plant-derived vaccines for developing countries | |
| Castillo Esparza et al. | Expression of the capsid protein of human papillomavirus in plants as an alternative for the production of vaccines. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170718 |
|
| MKLA | Lapsed |
Effective date: 20201203 |